

# **Kabra Drugs Limited**

September 09, 2024

CIN NO: L02423MP1989PLC005438

Regd. Off: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh. Phone: +91 98846 24100

To
Department of Corporate Services,
Bombay Stock Exchange Limited
Dalal Street, Fort, Mumbai -400001

Scrip Code: 524322 Security ID: KABRADG

**Subject: Submission of Annual Report** 

Dear Sir/ Madam,

With reference to the captioned subject and pursuant to Reg.34 of the SEBI (Listing and Disclosure Requirements) Regulations, we are submitting we enclose herewith Notice of the 35<sup>th</sup> Annual General Meeting of the Company to be convened on 30<sup>th</sup> September, 2024, at 10:00 AM at 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh – 452011.

The Annual Report of the Company has been sent to the shareholders and is enclosed herewith.

Kindly take the same on your record and acknowledge the receipt herewith

Thanking you

For Kabra Drugs Limited

Director
DIN: 02040505



Corp. Off: No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033.

Phone: +91 - 44 - 4356 4679 Email: kabradrugs@gmail.com



## KABRA DRUGS LIMITED

#### **Board of Directors**

Mr. N. Aravind Managing Director

Mr. Bangalore Venkatakrishnappa Ananth Kumar Chief Financial Officer & Whole Time Director

Mrs. Ananthkumar Shilpa Independent Woman Director

Mr. Kuniamuthur Nanjappan Anand Executive Director
Mrs. A Anitha Independent Director
Mrs. Monika Sanwal Company Secretary

#### **Auditors**

M/S. Rishi Sekhri and Associates Chartered Accounts

#### REGDISTRED OFFICE

208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh 452011.

## **CORPORATE OFFICE**

No:3, 2<sup>nd</sup> Floor, Swaminathan Street, West Mambalam, Chennai – 600 033.

## **Registrar & Transfer Agent**

M/s Skyline Financial Services Pvt.Ltd A/505, Dattani Plaza, Andheri-Kurla Road, Safeed Pool, Andheri (East), Mumbai, Maharashtra,400072

CIN: L02423MP1989PLC005438

Website: <a href="www.kabradrugs.com">www.kabradrugs.com</a>
Email: <a href="mailto:kabradrugs@gmail.com">kabradrugs@gmail.com</a>

## NOTICE

Notice is hereby given that the 35<sup>th</sup> Annual General Meeting of the Members of KABRA DRUGS LIMITED, will be held at 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh 452011 on Monday, 30<sup>th</sup> September 2024 at 10:00 A.M. to transact the following business: -

#### **ORDINARY BUSINESS:**

- 1. To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended March 31, 2024 and the reports of the Board of Directors and Auditors thereon.
- 2. To appoint a director in place of Mr. BANGALORE VENKATAKRISHNAPPA ANANTHKUMAR (DIN No. 08644948) who retires by rotation, and being eligible, offers himself for re-appointment.
- 3. Appointment of M/S PPN And Company Chartered Accountants, (FRN:013623S) as Statutory Auditors and fixing their remuneration for an initial term of five years.

To consider and if thought fit, to pass the following resolution as an ordinary resolution:

"RESOLVED THAT pursuant to the provisions of Section 139, 141, 142 and other applicable provisions, if any of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and pursuant to the recommendation of the Audit Committee of the Board of Directors, M/s PPN and Company Chartered Accountants, (FRN:013623S) be and is hereby appointed as the Statutory Auditors of the Company in place of the retiring Statutory Auditors M/s. Rishi Sekhri & Associates., Chartered Accountants, for an initial term of five consecutive years and who shall hold office from the conclusion of this 35th Annual General Meeting till the conclusion of 40th Annual General Meeting to be held in the financial year 2028-29.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to fix such remuneration and the reimbursement of out-of-pocket expenses, if any as may be determined by the Audit Committee and the Board of Directors of the Company.

RESOLVED FURTHER THAT the Board of Directors be and are hereby authorized to do all such necessary acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution."

#### **SPECIAL BUSINESS:**

#### 4. To shift the Registered Office of the company:

To consider and if thought fit, to pass with or without modification(s), the following resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 12(4), 12(5), 12(6) & 13(4) of the Companies Act, 2013 and other applicable provisions, if any, the consent of the members of the company be and is hereby accorded to shift the registered office of the company from Shop 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh 452011to No3, 2<sup>nd</sup> Floor, Swaminathan Street, West Mambalam, Chennai - 600033.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 12 and 13 and other applicable provisions of the Companies Act, 2013 (including any amendment thereto or re-enactment thereof) and the rules framed thereunder, the consent of members of the company be and is hereby accorded for substituting Clause II of the Memorandum of Association of the Company with the following clause:

II. The Registered office of the company will be situated in the state of Tamil Nadu

RESOLVED FURTHER THAT any Director of the Company, be and is hereby authorized to file all the necessary forms with the Registrar of Companies and to do all such acts, deeds, matters and things as are necessary for the purpose of giving effect to the above Resolution.

RESOLVED FURTHER THAT change in the place of registered office of the company be made in the name plates or board affixed at the registered office and in the letterheads, official publications, and documents of the company."

## 5. To consider and approve the re-appointment of Mr. B V ANATHA KUMAR (DIN:08644948) as the whole-time director of the company for a term of 2 years.

To consider and, if thought fit, to pass, the following resolution as Special Resolution:

"RESOLVED THAT, pursuant to the provisions of Section 196, 197, 198 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013, and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and provisions of the Articles of Association of the Company, the consent of the members be and is hereby accorded to re-appoint Mr. B V Anatha Kumar (DIN:08644948) as a Whole-Time Director to hold office for a period of 2 years with effect from 30 September 2024

"RESOLVED FURTHER THAT, in the interest of the organization and in view of the current financial condition of the Company and the economy as a whole, Mr. B V Anatha Kumar (DIN:08644948) has consented to be re-appointed as the Whole-Time Director of the Company without any remuneration until the Company's cash flows improve".

"RESOLVED FURTHER THAT, the term of office of Mr. B V Anatha Kumar as a Whole Time Director shall be subject to retirement by rotation".

# 6. Regularization of Mr. N. ARAVIND (DIN: 01895602) as Managing Director on the board of the company.

To consider and, if thought fit, to pass, the following resolution as a Special resolution:

"RESOLVED THAT pursuant to provision of Section 196, 197, 198 and 203 and other applicable provisions of the Companies Act, 2013 (including any statutory amendment(s) or modification(s) or re-enactment thereof), from time being in force, read with Schedule V of the Companies Act, 2013, including rules framed thereunder (the "Act"), based on the recommendation of the Nomination and Remuneration Committee and approval of the Board, consent of the Company be and hereby accorded to appoint Mr. N. Aravind (DIN: 01895602) who has signified his consent to be appointed as an Managing Director of the Company, to hold the office for a period of 5 (Five) years effective from 30 September 2024 on such terms and conditions and remuneration as set out in the appointment letter/agreement, to be entered into between the Company and Mr. N. Aravind (DIN: 01895602), material terms of which are set out in the Explanatory Statement annexed hereto, with liberty to the Board to alter and vary the terms and conditions of the said appointment letter/agreement in such manner as may be agreed between the Board and Mr. N. Aravind.

"RESOLVED FURTHER THAT in the absence of inadequacy of profits in any financial year during the tenure of Mr. N. Aravind as the Managing Director of the Company, he shall be paid the remuneration as set out in the Explanatory Statement referred to above as the Minimum Remuneration in accordance with the provisions of Schedule V of the Companies Act, 2013."

"RESOLVED FURTHER THAT Board of the Directors of the Company (hereinafter referred to as "Board" which term shall deemed to include any committee which the Board may have constituted or hereinafter constitute to exercise its power including the powers conferred by this Resolution) be and is hereby authorized to sign and executed deeds, application, documents and writing that may be required on behalf of the Company and to do all necessary acts, deeds, matter and things, which may be necessary, proper and expedient to give effect to the above resolution."

# 7. Change in designation of Mr. KUNIAMUTHUR NANJAPPAN ANAND (DIN: 03230186) as the Executive Director of the company:

To consider and, if thought fit, to pass, the following resolution as special resolution:

"RESOLVED THAT pursuant to the provisions of Section 149 and 152 read with rules made there under and other applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (including any statutory modifications or re-enactment thereof for the time being in force), consent of the members be and is hereby accorded to change in designation of MR. Kuniamuthur Nanjappan Anand (DIN: 03230186) from Non-Executive Independent Director to Executive Director, liable to retire by rotation.

"RESOLVED FURTHER THAT any of the Director for the time being be and is hereby severally authorized to sign and execute all such documents and papers as may be required for the purpose and file necessary e-form with the Registrar of Companies, Mumbai and to do all such acts, deeds and things as may considered expedient and necessary in this regard.

By the order of the Board of Directors For Kabra Drugs Limited

Sd/-KN. ANAND Director DIN: 03230186 Indore 02/09/2024

#### **NOTES:**

- 1. A member entitled to attend, and vote is also entitled to appoint a proxy to attend and vote instead of himself/herself and the proxy need not be a member. Proxies in order to be effective must be received by the company not less than 48 hours before the commencement of this meeting. Members/ proxies should bring their attendance slip duly filled in order to attend the meeting. A person can act as proxy on behalf of members" not exceeding fifty (50) and holding in the aggregate not more than ten percent of the total share capital of the company.
- 2. The Explanatory Statement pursuant to section 102 of the Companies Act, 2013 is annexed hereunder and forms part of the Notice.
- 3. In case of joint holders attending the meeting, only the joint holder who is higher in the order of names will be entitled to vote.
- 4. The Register of Members and Share Transfer Register of the Company will remain closed from Tuesday, September 24, 2024, to Monday, September 30, 2024 (both days inclusive).
- 5. Shareholders desiring any information as regards the accounts are requested to write to the Company at least 10 Days before the Annual General Meeting to enable the Management to keep the information ready.
- 6. The shareholders are hereby informed that all the correspondence in connection with the shares is addressed to the Registrar & Share Transfer Agent M/S Skyline Financial Services Pvt. Ltd, A/505, Dattani Plaza, Andheri-Kurla Road, Safeed Pool, Andheri (East), Mumbai, Maharashtra, 400072.
- 7. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in Securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participant with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN to the Company/ Skyline Financial Services Pvt. Ltd.
- 8. Members holding shares in single name and physical form are advised to make nomination in respect of their shareholding in the Company.
- 9. Members who hold shares in physical form in multiple folios in identical names or joint holding in the same order of names are requested to send the share certificates to Skyline Financial Services Pvt. Ltd, for consolidation into single folio.
- 10. To prevent fraudulent transactions, members are advised to exercise due diligence and notify the Company of any change in address or demise of any member as soon as possible. Members are also advised not to leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the Concerned Depository Participant and holdings should be verified.
- 11.Electronic copy of the Annual Report is being sent to all the members whose email IDs are registered with the Company/Depository Participant(s) for communication purposes unless any member has requested for a hard copy of the same. For members who have not registered their email address, physical copies of the Annual Report is being sent in the permitted mode.
- 12. Electronic copy of the Notice of the 35th Annual General Meeting of the Company inter alia indicating the process and manner of E-voting along with Attendance Slip and Proxy Form is being sent to all the members whose email IDs are registered with the Company/Depository Participant(s) for communication purposes unless any member has requested for a hard copy of the same. For members who have not registered their email address, physical copies of the Notice of the Annual General Meeting of the Company inter alia indicating the process and manner of E-voting along with Attendance Slip and Proxy Form is being sent in the permitted mode.

13.Members may also note that the Notice of the Annual General Meeting and the Annual Report for 2023-24 will also be available on the Company's website at www.kabradrugs.com The physical copies of the aforesaid documents will also be available at the Company's Registered Office for inspection during normal business hours (11.00 A.M. to 5.00 P.M.) on all working days except Saturdays and Sundays, up to and including the date of the Annual General Meeting of the Company. Even after registering for e-communication, members are entitled to receive such communication in physical form, upon making a request for the same by post. For any communication, the shareholders may also send requests to the Company's investor email id: kabradrugs@gmail.com.

#### SHAREHOLDER INSTRUCTIONS FOR E-VOTING

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014, the Company is pleased to offer e-voting facility as an alternate to physical voting to all the Members of the Company. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating e-voting to enable the Members to cast their votes electronically. E-voting is optional for the Members.

The instructions for shareholders voting electronically are as under:

- i. The voting period begins on 27.09.2024 AT 09.00 A.M. and ends on 29.09.2024 AT 5.00 P.M. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of 23rd September 2024 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- ii. Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- iii. Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.
  - Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.
  - In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.
- iv. In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020, on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above-said SEBI Circular, Login method for e-Voting and joining virtual meetings for Individual shareholders holding securities in Demat mode CDSL/NSDL is given below:

Type of Shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL	<ol> <li>Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. The option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi/ Easiest are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System Myeasi.</li> <li>After successful login the Easi / Easiest user will be able to see the e- Voting option for eligible companies where the e-voting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period.</li> <li>If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration.</li> <li>Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page or</li> <li>Click on https://evoting.cdslindia.com/Evoting/EvotingLogin The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.</li> </ol>
Individual Shareholders holding securities in demat mode with NSDL	1) If you are already registered for NSDL IDeAS facility, please visit the e- Services website of NSDL. Open web browser by typing the following URL: <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to E-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote E-Voting period or joining virtual meeting & voting during the meeting.  2) If the user is not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> . Select "Register Online for
	IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp

3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e., your sixteen-digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e- Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting

Individual
Shareholders
(Holding
securities in
demat mode)
login through
their
Depository
Participants

You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned website.

# Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738and 22-23058542-43.
Individual Shareholders holding securities in Demat mode with <b>NSDL</b>	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020990 and 1800 22 44 30

- v. Login method for e-Voting and joining virtual meetings for Physical shareholders and shareholders other than individual holding in Demat form.
  - 1) The shareholders should log on to the e-voting website www.evotingindia.com.
  - 2) Click on "Shareholders" module.
  - 3) Now enter your User ID
    - a. For CDSL: 16 digits beneficiary ID,
    - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID.
    - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
  - 4) Next enter the Image Verification as displayed and Click on Login.
  - 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.

If you are a first-time user follow the steps given below:

_	For Members holding shares in Demat Form and Physical Form			
PAN	Enter your 10-digit alpha-numeric PAN issued by Income Tax Department			
	(Applicable for both demat shareholders as well as physical shareholders)			
	members who have not updated their PAN with the Company/Depository			
	Participant are			
	requested to use the sequence number which is printed on Postal Ballot /			
	Attendance Slip indicated in the PAN field.			
Dividend	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as			
Bank	recorded in your demat account or in the company records in order to login.			
Details <b>OR</b>				
Date of	Both the details are not recorded with the depository or company please enter the			
Birth	member id / folio number in the Dividend Bank details field as mentioned in			
(DOB)	instruction (iv).			

- (vi) After entering these details appropriately, click on "SUBMIT" tab.
- (vii) Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (viii) For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant **<KABRA DRUGS LIMITED** > on which you choose to vote.
- (x) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- (xiii) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
- (xv) If a demat account holder has forgotten the login password, then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvi) Shareholders can also cast their vote using CDSL's mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. Please follow the instructions as prompted by the mobile app while voting on your mobile.

(xvii) Note for Non – Individual Shareholders and Custodians

- Non-Individual shareholders (i.e., other than Individuals, HUF, NRI etc.) and Custodian are required to log on to <a href="www.evotingindia.com">www.evotingindia.com</a> and register themselves as Corporates.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

Institutional Members / Bodies Corporate (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution / Authority letter etc. together with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote through e-mail at <a href="www.kabradrugs.com">www.kabradrugs.com</a> with a copy marked to helpdesk.evoting@cdslindia.com on or before 29.09.2024 up to 5:00 pm without which the vote shall not be treated as valid.

Investor who became members of the Company subsequent to the dispatch of the Notice / Email and holds the shares as on the cut-off date i.e., 23 September 2024 are requested to send the written / email communication to the Company at www.kabradrugs.com by mentioning their Folio No. / DP ID and Client ID to obtain the Login- ID and Password for e-voting.

The Company has appointed JAY JAIN & ASSOCIATES, Practicing Company Secretary (Membership No. 55129 CP No. 23109) as the Scrutinizer for purpose of E voting to count the votes casted in favour or against the resolution proposed for all the items of the Notice as mentioned in the Notice and to comply with the provisions of Section 108 of the Companies Act, 2013

The Results shall be declared on or after the AGM of the Company. The Results declared along with the Scrutinizer's Report shall be placed on the Company's website and on the website of CDSL within two (2) days of passing of the resolutions at the AGM of the Company and communicated to BSE Limited.

Subject to receipt of requisite number of votes, the Resolutions shall be deemed to be passed on the date of the  $35^{th}$  Annual General Meeting i.e., Monday, September 30, 2024.

As required by section 102 of the companies act, 2013 ("the act"), the following explanatory statement sets out all material facts relating to the businesses mentioned under item numbers 4 and 5 of the accompanying notice dated august 20, 2024

#### ITEM NO. 4

Based on the recommendation of Nomination & Remuneration Committee by its resolution passed at the meeting held on August 14, 2024, the Board of Directors vide their resolution passed on August 14, 2024, re-appointed Mr. B V Anatha Kumar (DIN:08644948) as the whole-time Director of the Company subject to the approval of members of the Company.

In the interest of the organization and in view of the current financial condition of the Company and the economy as a whole B V Anatha Kumar (DIN:08644948) has consented to be re-appointed as the Whole-Time Director of the Company without any remuneration until the Company's cash flows improve. The Board of

Directors considers the re-appointment of B V Anatha Kumar to be in the best interest of the Company.

The terms and conditions of his re-appointment are set out in the resolution proposed to be passed, including the following:

- a) Term of re-appointment -2 Years. He shall be liable to retire by rotation.
- b) Remuneration-Nil

A brief profile covering the details of his qualification, experience etc. as required pursuant to Secretarial Standards on general meeting is annexed to this notice. The Board believes that the reappointment of B V Anatha Kumar (DIN:08644948) shall be greatly beneficial, especially in the operations of the Company.

The Directors, therefore, recommend the resolution appearing under Item No.4 of the accompanying Notice for your approval.

None of the Directors, key managerial personnel and their relatives is concerned or interested in the resolutions

#### ITEM NO. 5

Based on the recommendation of Nomination & Remuneration Committee by its resolution passed at the meeting held on August 14, 2024 the Board of Directors vide their resolution passed on August 14, 2024 appointed Mr. N. Aravind (DIN: 01895602) as an Additional Director of the Company in the capacity of Managing Director for a term of 5 years with effect from 30 September 2024 In terms of section 160 of the Companies Act, 2013, the Board Governance, Nomination and Remuneration Committee and the Board have recommended the appointment of Mr. N. Aravind as an Independent Director pursuant to the provisions of Sections 149 and 152 of the Companies Act, 2013.

The Members may note that the Company has received a letter of consent from Mr. N. Aravind signifying his willingness to be appointed as Managing Director, a declaration under section 164 of the Companies Act, 2013 and other statutory disclosures/declarations as required under the law, the essential terms and condition of his appointment and remuneration are as under.

- a) Mr. N. Aravind shall be responsible for overseeing for the day-to-day operations and management of the Company and such other matters as identified by the Board from time to time. Mr. N. Aravind shall devote his whole time and attention to the business of the Company
- b) Period of Agreement: 5 Years
- c) Minimum Remuneration: In the event of loss or inadequacy of profits in any year during the tenure of the Managing Director shall be paid remuneration as above as minimum remuneration.
- d) Sitting fees: Mr. N. Aravind shall not be paid sitting fees for attending the Board meetings and meetings of the Committee in which he may be nominated as a member.

The Office of the Managing Director will not be liable to retire by rotation. Mr. N. Aravind does not hold any shares in the Company either by himself or for any other person on a beneficial person.

The draft of the appointment letter/agreement shall be open for inspection by the Members at the Registered office of the Company during the normal business hours on any working day, excluding Sunday. Having regard to his qualifications, experience and association with the Company, the Board of Directors considers that it will be in the interest of the Company to appoint Mr. N. Aravind as the Managing Director of the Company for a term of 5 years.

Your directors recommend the Resolution set out in Item No. 5 of this AGM Notice to the Members for their consideration and approval by Special Resolution.

None of the Promoters, Directors, Key Managerial Personnel of the Company or their relative are in any way concerned or interested, financially or otherwise, in the Resolution except Mr. N. Aravind.

#### **ITEM 6:**

Mr. Kuniamuthur Nanjappan Anand was appointed as an Non-Executive Independent Director w.e.f. June 09, 2022. On the recommendation of Nomination and Remuneration Committee, the Board changed the designation of Mr. Kuniamuthur Nanjappan Anand from Non-Executive Independent Director to Executive Director, liable to retire by rotation, subject to approval of Members.

Mr. Kuniamuthur Nanjappan Anand has given his consent to be appointed as an Executive Director of the Company and necessary documents, including his consent in Form DIR 2, Disclosure of interest in other entities in Form MBP -1, Declaration in Form DIR 8 and Declaration of non-debarment from holding the office of Director pursuant to any SEBI order and MCA Order, has been received.

#### By the order of the Board of Directors

For Kabra Drugs Limited

Sd/-

KN. ANAND Director DIN: 03230186

Indore 02/09/2024

## DIRECTORS' REPORT

#### Dear Shareholders,

Your directors here by present the 35<sup>th</sup> Annual Report together with the Audited statements of Accounts for the financial year ended on 31<sup>st</sup> March 2024.

#### **OPERATIONS REVIEW:**

(Rs. In lacs)

		(2250 222 20005)
Particulars	F.Y. 2023-24	F.Y. 2022-23
Revenue from Operations	-	-
Other Income	-	0.64
Total Revenue	-	0.64
Total Expenses	73.61	34.43
Profit Before Tax	(73.61)	(33.79)
Тах	-	1
Profit after Tax	(73.61)	(33.79)
EPS	(1.68)	(0.77)

#### **DIVIDEND:**

Considering the loss incurred in the current financial year and accumulated losses, your directors have not recommended any dividend for the financial year under review.

#### CLOSURE OF REGISTER OF MEMBERS AND SHARE TRANSFER BOOKS:

The Book closure shall be from 24.09.2024 to 30.09.2024 (Both inclusive)

#### TRANSFER TO RESERVES:

The Company has not transferred any amount to Reserves for the period under review.

# TRANSFER OF UNCLAIMED/UNPAID AMOUNTS TO THE INVESTOR EDUCATION AND PROTECTION FUND ("IEPF"):

No amount to be transferred to Investor Education and Protection Fund.

#### **SHARE CAPITAL:**

The issued, subscribed and paid-up capital of the Company is Rs. 4,38,86,000/- divided into 4,38,86,00 equity shares of Rs 10/- each. There has been no change in the share capital of the Company during the year.

#### SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES:

The Company does not have any subsidiary, associate companies & joint ventures.

# MATERIAL CHANGES AND COMMITMENTS IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

No material changes and commitments affecting the financial position of the company have occurred between the end of financial year to which the financial statements relate and the date of the Directors' Report.

#### **DEPOSIT:**

Company has not accepted any deposits within the meaning of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

#### DISCLOSURE UNDER SECTION 67 (3) (c) OF THE COMPANIES ACT, 2013:

No disclosure is required under section 67 (3) (c) of the Companies Act, 2013 read with Rule 16(4) of the Companies (Share Capital and Debentures) Rules, 2014, in respect of voting rights not exercised directly by the employees of the Company as the provisions of the said section are not applicable.

#### PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the notes to the Financial Statements.

#### **RELATED PARTY TRANSACTIONS:**

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of the business. There are no materially significant related party transactions made by the company with Promoters, Key Managerial Personnel or other designated persons which may have potential conflict with interest of the company at large.

# SIGNIFICANT ORDERS PASSED BY THE REGULATORS, COURTS OR TRIBUNALS IMPACTING GOING CONCERN AND COMPANY'S OPERATIONS:

To the best of our knowledge, the company has not received any such orders passed by the regulators, courts or tribunals during the year, which may impact the going concern status or company's operations in future.

#### **BOARD DIVERSITY:**

The Company recognizes that building a Board of diverse and inclusive culture is integral to its success. The Board considers that its diversity, including gender diversity, is a vital asset to the business.

The Board has adopted a Board diversity policy which sets out the approach to diversity of the Board of Directors.

#### **POLICIES:**

The Company has adopted the following policies and the same are available in the website of the Company http://www.kabradrugs.com/

- i) Whistle Blower Policy/ Vigil Mechanism
- ii) Policy of Directors' Appointment and remuneration
- iii) Policy on determining materiality of events
- iv) Policy on documents preservation and archival
- v) Nomination and; Remuneration policy
- vi) Policy on related party transactions
- vii) Policy on sexual harassment of women at workplace (prevention, prohibition and redressal) Act 2013
- ix) Policy on code of conduct for prevention of Insider Trading and Fair Disclosure of unpublished Price Sensitive Information.

# DISCLOSURE AS PER POLICY ON SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT 2013:

The Company has zero tolerance for Sexual harassment at workplace and has adopted a policy on prevention, prohibition and redressal of Sexual Harassment at work place in line with the requirements of the Sexual Harassment of women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and rules framed thereunder which has been made available on the Company's website (www.kabradrugs.com).

Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

Your directors state that during the year under review, there was no case filed pursuant to the Sexual Harassment of the Woman at the Workplace (Prevention, Prohibition and Redressal) Act, 2013.

#### **HUMAN RESOURCES:**

The Company believes that human capital is its biggest asset and immensely values its human resources. The Company acknowledges that employee participation and involvement is the key to sustained growth and hence encourages various measures to promote the same. The Company is of the opinion that motivated employees are very crucial to the growth of the organization and hence puts in a lot of emphasis on promoting employee engagement at all levels.

#### **RISK MANAGEMENT:**

The Company has developed and implemented a Risk Management Policy. The policy identifies the threat of such events as "Risks", which if occurred will adversely affect value to shareholders, ability of Company to achieve objectives, ability to implement business strategies, the manner in which the Company operates and reputation. Such risks are categorized into Strategic Risks, Operating Risks and Regulatory Risks.

The framework defines the process for identification of risks, its assessment, mitigation measures, monitoring and reporting. While the Company, through its employees and Executive Management, continuously assess the identified Risks, the Audit Committee reviews the identified Risks and its mitigation measures annually.

#### INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. The Company has an Internal Audit department with adequate experience and expertise in internal controls, operating system and procedures. The system is supported by documented policies, guidelines and procedures to monitor business and operational performance which are aimed at ensuring business integrity and promoting operational efficiency.

#### VIGIL MECHANISM / WHISTLE BLOWER POLICY:

The Company has a vigil mechanism named Whistle Blower Policy to deal with instances of fraud and mismanagement, if any.

#### **DIRECTORS AND KEY MANAGERIAL PERSONNEL:**

In accordance with the provisions of Section 152 of the Companies Act, Mr. Bangalore Venkata Krishnappa Ananth Kumar (DIN: 08644948), Whole-Time Director of the Company retires by rotation at the forthcoming Annual General Meeting and being eligible has offered himself for re-appointment. The Board recommends his reappointment. The resolution for his re-appointment is incorporated in the Notice of the ensuing Annual General Meeting.

After the closure of the financial year, in the Board Meeting held on 14<sup>th</sup> August 2024, Mr. N. Aravind (DIN: 01895602) appointed as an Additional Director designated as the Managing Director of the Company subject to the approval of his appointment by the members in the general meeting. The Board recommends his appointment as the Managing Director. The resolution for his appointment is incorporated in the Notice of the ensuing Annual General Meeting.

On the re-commendation of the Nomination and Remuneration committee, in the Board Meeting held on 02<sup>nd</sup> September 2024, and subject to the approval of the members in the general meeting, Mr. Kuniamuthur Nanjappan Anand (DIN: 03230186), who was appointed as Non-Executive Independent Director in year 2022, be and is hereby appointed as the executive director of the company liable to be retire by rotation. The resolution for his change in designation is incorporated in the Notice of the ensuing Annual General Meeting.

During the year under review, there have been no circumstances affecting their status as independent directors of the Company. No Director of the Company is disqualified under any law to act as a director.

During the year under review, the non-executive directors of the Company had no pecuniary relationship or transactions with the Company, other than sitting fees, commission and reimbursement of expenses incurred by them for the purpose of attending meetings of the Board/ Committee of the Company.

Considering the above changes, following is the composition of the Board of the Company.

Sr. No	Name of the Directors	Designation	Date of Appointment
1.	BANGALORE	Chief Financial Officer & Whole	29/01/2020
	VENKATAKRISHNAPPA	Time Director	
	ANANTH KUMAR		
2.	KUNIAMUTHUR NANJAPPAN	Executive Director	02/09/2024
	ANAND		
3.	ANANTHKUMAR SHILPA	Independent Woman Director	19/02/2020
4.	ANAND ANITHA	Independent Director	14/07/2022
5.	N. ARAVIND	Managing Director	14/08/2024
6.	MONIKA SANWAL	Company Secretary & Compliance	14/07/2022
		Officer	

#### **DECLARATION BY INDEPENDENT DIRECTORS:**

The Company has received necessary declaration from each Independent Director under Section 149 (7) of the Companies Act, 2013, that they meet the criteria of independence laid down in Section 149(6) of the Companies Act, 2013.

#### NUMBER OF MEETINGS OF THE BOARD:

During the financial Year 2023-2024, the Board met seven (7) times. The details of the number of meetings of the Board held during the Financial Year 2023-24 and the attendance of the Directors is enshrined below:

Sr. No	Date of the Board Meeting	Number of Directors present
1	30/05/2023	4
2	14/08/2023	4
3	02/09/2023	4
4	13/11/2023	4
5	15/12/2023	4
6	23/01/2023	4
7	14/02/2024	4

## **COMMITTEES OF THE BOARD:**

The Board of Directors has the following Committees: -

- 1. Audit Committee
- 2. Nomination and Remuneration Committee
- 3. Stakeholders' Relationship Committee

The details of the Committees along with their composition, number of meetings and attendance at the meetings are provided below:

1. The Audit Committee of the Company constituted comprises of Three Directors being Mr. B V Anatha Kumar, Mr. K N Anand and Mrs. A. Anitha. During the year, the audit committee met 4 times i.e 30.05.2023, 14.08.2023, 13.11.2023, and 23.01.2024 with the attendance of the members as under: -

Name of the member	No of meetings attended		
	Held	Attended	
Mr. B V Anatha Kumar	4	4	
Mr. K N Anand	4	4	
Mrs. A. Anitha	4	4	

2. Nomination and Remuneration Committee constituted comprises of Three Directors being Mr. B V Anatha Kumar, Mr. KN. Anand, Mrs. A. Anitha. During the year, the Nomination & remuneration committee met 4 times i.e 30.05.2023, 14.08.2023 13.11.2023, and 23.01.2024 with the attendance of the members as under:

Name of the member	No of meetings attended		
	<u>Held</u>	Attended	
Mr. B V Anatha Kumar	4	4	
Mr. K N Anand	4	4	
Mrs. A. Anitha	4	4	

3. 'Stakeholders Relationship Committee- The Board of Directors of the Company has set up 'Stakeholders Relationship Committee' in order to align it with the provisions of Section 178 of the Companies Act, 2013.

The Committee has been constituted to strengthen the investor relations and to inter-alia, look into issues relating to shareholders grievances pertaining to transfer of shares, non-receipt of declared dividends, non-receipt of Annual Report, issues concerning de-materialization etc.

This committee comprised of Three Directors being Mr. B V Anatha Kumar, Mr. KN.Anand and Mrs. A. Anitha. During the year, Two committee meeting held on 13.11.2023, and 23.01.2024 respectively all committee members present at the meeting.

#### **BOARD EVALUATION:**

Pursuant to the provisions of the Schedule IV, clause VIII of the Companies Act, 2013 the Board has carried out an evaluation of its own performance, the directors individually as well as the evaluation of the working of its Audit, Appointment & Remuneration Committees. The performance evaluations of Independent Directors were also carried out and the same was noted. Independent Directors in their meeting decided to bring more transparency in their performance and bring more responsibility while taking any policy decisions for the benefit of the shareholders in general.

#### REMUNERATION POLICY:

The Board has on the recommendation of the Nomination and Remuneration Committee, framed a policy for selection and appointment of Directors, Key Managerial Personnel and Senior Management and their remuneration.

# REMUNERATION OF THE DIRECTORS/ KEY MANAGERIAL PERSONNEL (KMP)/ EMPLOYEES:

No Directors/ Key Managerial Personnel are drawing any remuneration. Hence, the information required pursuant to Section 197 read with Rule 5 (1) (i) of The Companies (Appointment and Remuneration) Rules, 2014 in respect of ratio of remuneration of each director to the median remuneration of the employees of the Company for the Financial year is not given.

#### SEPARATE MEETING OF THE INDEPENDENT DIRECTORS

As required under Clause VII of Schedule IV of the Companies Act, 2013, the Independent Directors held a Meeting on 13<sup>th</sup> November 2023, without the attendance of Non-Independent Directors and members of Management.

#### FAMILIARIZATION PROGRAM FOR THE INDEPENDENT DIRECTORS:

The Independent Directors have been updated with their roles, rights and responsibilities in the Company by specifying it in their appointment letter along with necessary documents, reports and internal policies to enable them to familiarize with the Company's procedures and practices. The Company has through presentations, at regular intervals, familiarized and updated the Independent Directors with the strategy, operations and functions of the Company and Engineering Industry as a whole.

#### **AUDITORS AND AUDITORS' REPORT:**

M/s PPN and Company Chartered Accountants, (FRN:013623S) appointed as the Statutory Auditors of the Company in place of the retiring Statutory Auditors M/s. Rishi Sekhri & Associates., Chartered Accountants, for an initial term of five consecutive years and who shall hold office from the conclusion of this 35th Annual General Meeting till the conclusion of 40th Annual General Meeting to be held in the financial year 2028-29 at such remuneration and out of pocket expenses , as may be decided by the Board of Directors of the Company on the recommendation of the Audit Committee.

The observations made by the Auditors' in their Auditors' Report and the Notes on Accounts referred to in the Auditors' Report are self-explanatory and do not call for any further comments.

### SECRETARIAL AUDIT AND SECRETARIAL AUDITORS' REPORT:

Pursuant to provisions of section 204 of the Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 the Company has appointed Mrs. Anshu Chouhan & Associates, Company Secretary in practice to undertake the Secretarial Audit of the Company. The Secretarial Audit report in the prescribed Form No MR-3 is annexed herewith.

# QUALIFICATION IN SECRETARIAL AUDIT REPORT AND EXPLANATIONS BY THE BOARD: -

Sr. No.	Qualifications made by Secretarial Auditor	Explanations by the Board
a)	The company has not complied with certain regulation of SEBI (LODR), Regulation, 2015 as regards publication of Notice of Board Meeting, Notice of AGM,	
b)	quarterly results.  As per section 138 of the Companies Act, 2013, the Company is required to appoint Internal Auditor. The Company has not appointed	The size of operation of the Company is very small, it is not viable to appoint Internal Auditor but the Company has established the internal control system.
	Internal Auditor.	

c)	companies Act 2013	as	The company will take necessary steps to update Statutory Register as per companies Act 2013.
	is yet to be updated.		

#### **ANNUAL RETURN:**

In terms of Sections 92(3) and 134(3)(a) of the Act, annual return for the financial year 2022-2023 will be made available on the Company's website once filed with Registrar of Companies and can be viewed at the below mentioned link: <a href="https://www.kabradrugs.com/">https://www.kabradrugs.com/</a>.

#### REPORT ON CORPORATE GOVERNANCE & MANAGEMENT DISCUSSION & ANALYSIS:

As per the SEBI (Listing Obligations and Disclosures Requirements), 2015, introduced pursuant to SEBI Notification No. SEBI/LAD-NRO/GN/2015-16/013 dated September 2, 2015, which became effective from December 1, 2015 read with Regulation 15(2)(a) of SEBI (Listing Obligations and Disclosures Requirements), 2015, Regulation 27(2)(a) is applicable to only those listed entities having paid-up Equity Share Capital exceeding Rs. 10 Crores and Net Worth exceeding Rs. 25 Crores.

In light of the same the Company has informed BSE Limited regarding the non-applicability of Regulation 27(2) (a) of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015.

#### **CORPORATE SOCIAL RESPONSIBILITY INITIATIVES:**

The Company has not developed and implemented any Corporate Social Responsibility initiative under the provisions of Section 135 of the Companies Act, 2013, read with Rule 9 of Companies (Corporate Social Responsibility Policy) Rules, 2014, as the said provisions are not applicable.

#### **PARTICULARS OF EMPLOYEES:**

In terms of the provisions of Section 197(12) of the Act read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is not required to be given as there were no employees coming within the purview of this section.

#### CODE OF CONDUCT FOR DIRECTORS AND SENIOR MANAGEMENT

The Board of Directors had adopted a Code of Conduct for the Board Members and employees of the Company. This Code helps the Company to maintain the Standard of Business Ethics and ensure compliance with the legal requirements of the Company.

The Code is aimed at preventing any wrong doing and promoting ethical conduct at the Board and by employees. The Compliance Officer is responsible to ensure adherence to the Code by all concerned and is available on the Company's website.

The Code lays down the standard of conduct which is expected to be followed by the Directors and the designated employees in their business dealings and in particular on matters relating to integrity in the work place, in business practices and in dealing with stakeholders.

All the Board Members and the Senior Management personnel have confirmed compliance with the Code.

#### TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

The details of conservation of energy, technology absorption etc. as required to be given under Section 134(3)(m) of the Companies Act, 2013 read with Rule, 8 of The Companies (Accounts) Rules, 2014, are not applicable to Company, as our Company has not carried out in the manufacturing activities. The foreign exchange earnings on account of the operation of the Company during the year was Rs. Nil.

# DISCLOSURE UNDER SECTION 197(12) OF THE COMPANIES ACT, 2013 AND OTHER DISCLOSURES AS PER RULE 5 OF COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:

Pursuant to Section 197(12) of the Companies Act, 2013 and Rule 5 of Companies (Appointment & Remuneration) Rules, 2014, every Listed Company mandate to disclose in the Board's Report the ratio of the remuneration of each director to the permanent employee's remuneration. However, since there is no permanent employee in the Company, no disclosure under the said provision has been furnished.

#### **DIRECTORS' RESPONSIBILITY STATEMENT:**

The Directors' Responsibility Statement referred to in clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013, shall state that:

- a) In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation by way of notes to accounts relating to material departures;
- b) The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the loss of the Company for that period;
- c) The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- e) Directors have prepared the accounts on a "going concern basis".
- f) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

#### MAINTENANCE OF COST RECORDS

The provisions pertaining to maintenance of cost records as specified by the Central Government under subsection (1) of section 148 of the Companies Act, 2013, are not applicable to the Company.

# THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 DURING THE YEAR ALONG WITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR:

During the Financial Year 2023-24, there was no application made and proceeding initiated /pending under the Insolvency and Bankruptcy Code, 2016, by any Financial and/or Operational Creditors against your Company.

As on the date of this report, there is no application or proceeding pending against your company under the Insolvency and Bankruptcy Code, 2016.

# THE DETAILS OF DIFFERENCE BETWEEN THE AMOUNT OF VALUATION AT THE TIME OF ONE-TIME SETTLEMENT AND THE VALUATION DONE AT THE TIME OF TAKING A LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF:

During the Financial Year 2023-24, the Company has neither taken any loan nor done any settlement with its Bankers.

# DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS:

During the reporting period, no significant and material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

#### **ACKNOWLEDGMENT:**

Your directors would like to express their sincere appreciation for the assistance and co-operation received from the Banks, Government Authorities, Customers, and Shareholders during the year. Your directors also wish to take on record their deep sense of appreciation for the committed services of the employees at all levels, which has made our Company successful in the business.

By the Order of the Board Kabra Drugs Limited

Sd/-KN.ANAND Director DIN: 03230186

Indore 02.09.2024

#### Annexure to Director's Report

#### MANAGEMENT DISCUSSION ANALYSIS REPORT

#### 1. INDUSTRY STRUCTURE AND DEVELOPMENTS:

As of now the Company is not engaged in any activity and the management is looking for a right opportunity to make the Company operational.

#### 2. OVERALL REVIEW:

Due to scarcity of working capital funds, the Company is not able to perform any business activities. To make the Company operational, the board is making its best effort to implement the cost reduction measures to the extent feasible. Several cost cutting measures have already been undertaken by the Company.

#### 3. RISK AND CONCERNS:

The Company's future development would depend upon the commencement of its operational activities

#### 4. INTERNAL CONTROLS SYSTEMS AND THEIR ADEQUACY:

The Company is following a proper and adequate system of internal controls in respect of all its activities. Further all transaction entered into by the Company are fully authorised, recorded and reported correctly

#### 5. FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:

During the year under review, the Company did not carry out any activity.

#### **6. CAUTIONARY STATEMENT:**

Statements in this Management Discussion and Analysis describing the company's objectives, projections, estimates and expectations may be forward looking statement within the meaning of applicable laws and regulations. Actual results might differ materially from those either expressed or implied.

For and on behalf of Kabra Drugs Limited

Sd/-B.V. Ananth Kumar Chief Financial Officer

#### Form No. MR-3

## SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED 31ST MARCH 2024

(Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No.9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

To.

The Members.

#### **KABRA DRUGS LIMITED**

Indore

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. KABRA DRUGS LIMITED (hereinafter called the company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, We hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on **March 31, 2024** complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have also examined the following with respect to the new amendment issued vide SEBI Circular number CIR/CFD/CMD1/27/2019 dated 8th February 2019 (Regulation 24A of SEBI(LODR) Regulations 2015).

- (a) all the documents and records made available to us and explanation provided by the Company,
- (b) the filings/submissions made by the Listed Entity to the Stock Exchanges,
- (c) website of the listed entity,
- (d) books, papers, minute books, forms and returns filed with the Ministry of Corporate Affairs and other records maintained by the Company for the financial year ended on 31st March 2024 according to the provisions as applicable to the Company during the period of audit and subject to the reporting made hereinafter and in respect of all statutory provisions listed hereunder:
- i. The Companies Act, 2013 (the Act) and the Rules made there under;
- ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under.
- iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under.
- iv. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
  - a. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time.
  - b. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended from time to time;
  - c. The Securities and Exchange Board of India (Prohibition of Insider Trading Regulations, 2015 as amended from time to time;
  - d. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended from time to time;

#### I hereby report that

- a. The Listed Entity has generally complied with the provisions of the above Regulations and circulars/guidelines issued thereunder, except mentioned in this report.
- b. As informed by the management of the Company, there were no actions taken against the listed entity/its promoters/directors either by SEBI or by Stock Exchanges (including under the Standard Operation Procedures issued by SEBI through various circulars) under the aforesaid Acts/Regulations and circulars/guidelines issued thereunder.

I have also examined the compliance with the applicable clauses of the following:

- (i) The Listing Agreements entered into by the Company with the Stock Exchanges, where the Securities of the Company are listed and the uniform listing agreement with the said stock exchanges pursuant to the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- (ii) Secretarial Standards with respect to Meetings of Board of Directors (SS-1) and General Meetings (SS-2) issued by the Institute of Company Secretaries of India as amended from time to time.

It is reported that during the period under review, the Company has been generally regular in complying with the provisions of the Act, Rules, Regulations and Guidelines, as mentioned above except:

- i. As per section 138 of the Companies Act, 2013, the Company is required to appoint Internal Auditor. The Company has not appointed Internal Auditor.
- ii. Statutory Registrar as per companies Act 2013 is in the process of updation.
- iii. The company is rated as GSM: stage 4 by Stock Exchange (Trading Restricted- on account of GSM)
- iv. The Annual report 2022 -23 of the company is not in compliance with Companies Act, 2013

I further report that there were no actions/events in the pursuance of

- 1. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 and the Employees Stock Option Scheme, 2007 approved under the provisions of the Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999;
- 2. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009
- 3. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998
- 4. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
- 5. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial borrowings; requiring compliance thereof by the Company during the Financial Year under review.

I further report that, based on the information provided by the Company, its officers and authorized representatives during the conduct of the audit, in our opinion, adequate systems and control mechanism exist in the Company to monitor and ensure compliance with other general laws.

I further report that the compliance by the Company of applicable financial laws, like direct and indirect tax laws, has not been reviewed in this Audit since the same have been subject to review by Statutory Auditors and other designated professionals.

For Anshu Chouhan & Associates Practising Company Secretary

> Sd/-ACS No: A45198

Place: Mumbai Date: 13/08/2024

UDIN: A045198F000971156

#### Annexure to MR 3

#### ANNEXURE-A

To,
The Members,
KABRA DRUGS LIMITED
Indore

Our report of even date is to be read along with this letter.

- 1. Maintenance of secretarial records is the responsibility of management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
- 2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
- 3. I have not verified the correctness and appropriateness of financial records and books of accounts of the company.
- 4. Wherever required, I have obtained the Management Representation about the compliance of laws, rules and regulations and happening of events, etc.
- 5. The compliance of the provisions of corporate and other applicable laws, rules and regulations, standards is the responsibility of the management. Our examination was limited to the verification of procedures on test basis.
- 6. The Secretarial Audit Report is neither an assurance as to the future viability of the company not of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For Anshu Chouhan & Associates Practising Company Secretary

Sd/-

ACS No: A45198

Place: Mumbai Date: 13/08/2024

UDIN: A045198F000971156

#### GENERAL SHAREHOLDERS INFORMATION:

Financial Year 1st April 2023 to 31st N		March 24	
Date and time of Annual General Monday, 30th September		er 2024 at 10:00 A.M.	
Venue of Annual General Meeting 208, Swadesh Bhavan, 2		2 Press Complex, AB Road, Indore,	
	Madhya Pradesh 45201	1, IN.	
Dates of Book Closure	24.09.2024 to 30.09.20	24	
Listing on Stock Exchange	BSE Limited, Mumbai		
Stock Code and Scrip ID 524322 (BSE) and KAI		BRADG (BSE)	
Demat ISIN No. INE323K01017			
Financial Calendar (tentative schedule			
Unaudited Results for the quarter ending 30.06.2023		Before 15th August, 2023	
Unaudited Results for the quarter ending 30.09.2023		Before 15th November, 2023	
Unaudited Results for the quarter ending 31.12.2023		Before 15th February, 2024	
Unaudited Results for the quarter ending 31.03.2024; or		Before 15th May, 2024	
In case company take Audited Results for the Whole Financial Year.		Before 30th May, 2024	

## CATEGORIES OF SHAREOWNERS AS ON 31.03.2024:

Category	No. of Shares Held	Voting Strength (%)
Promoters	0	0.00
Individuals		
Share Capital up to Rs. 2 Lakh	26,55,424	60.51
Share Capital in excess of Rs. 2 Lakh	15,45,624	35.22
Bodies Corporate	116755	2.66
NRIs	15,600	0.36
Clear Member	0	0
Hindu Undivided Families	52,923	1.21
Firm	2,274	0.05
Total	43,88,600	100.00

## **DISTRIBUTION OF SHAREHOLDING AS ON 31.03.2024:**

Share Balance	Holders	% of Total	Total Shares	% of Total
Up To 500	6490	88.13	1107044	25.23
501 To 1000	428	5.81	359227	8.19
1001 To 2000	244	3.31	371324	8.46
2001 To 3000	69	0.94	174956	3.99
3001 To 4000	23	0.31	81593	1.86
4001 To 5000	25	0.34	116069	2.64
5001 To 10000	42	0.57	296649	6.76
10000 and above	43	0.58	1881738	42.88
Total	7364	100.00	4388600	100.00

## STOCK MARKET DATA:

The monthly movement of Equity Share prices on BSE during the year is summarized below: -

Month	Highest (Rs)	Lowest (Rs)
Apr 23	5.57	5.40
May 23	5.40	5.40
Jun 23	5.40	5.40
Jul 23	5.91	5.11
Aug 23	5.68	3.76
Sep 23	4.26	3.18

Oct 23	6.25	4.47
Nov 23	5.66	5.12
Dec 23	5.39	4.87
Jan 24	6.85	5.65
Feb 24	6.85	6.85
Mar 24	7.19	6.85

#### REGISTRAR AND SHARE TRANSFER AGENT:

Skyline Financial Services Pvt. Ltd, A/505, Dattani Plaza, Andheri-Kurla Road, Safeed Pool, Andheri (East), Mumbai, Maharashtra,400072

Telephone No.: 022 - 28511022 / 022 49721245 E-mail:

#### **SHARE TRANSFER SYSTEM:**

Transfer of Shares in Physical form are registered and dispatched within 3 weeks from the date of their receipts, subject to the documents being valid and complete in all respects. Transfer of shares are processed by the Share Transfer Agents and approved by the Share Transfer Committee called as "Investor / Shareholders Grievance Committee", which meets at frequent intervals. Share transfers are registered and returned within 15 days from the date of receipt, if the relevant documents are complete in all respect.

#### ADDRESS FOR CORRESPONDENCE:

208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh 452011.

#### INVESTORS CORRESPONDENCE/ COMPLAINTS TO BE ADDRESS TO:

KN. ANAND-Director and E-mail: kabradrugs@gmail.com

#### DEMATERIALIZATION OF SHARES AND LIQUIDITY:

The Equity Shares of your company are traded in compulsory dematerialization form by all investors. The company has entered into agreements with both existing Depositories, National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) enabling the investors to hold shares of the company in electronic form through the depository of their choice.

Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

Number of complaints filed during the financial year 2023-24: Nil Number of complaints disposed of during the financial year 2023-24: NA Number of complaints pending as on end of the financial year: NA

#### CEO / CFO CERTIFICATE

# (Regulation 17(8) and Part B of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Board of Directors KABRA DRUGS LIMITED Indore

#### Dear Sir.

I, the undersigned, in my respective capacities as Director of the KABRA DRUGS LIMITED ("the Company") to the best of our knowledge and belief certify that:

- 1. I have reviewed the Financial Statements and the Cash Flow Statement for the year ended 31st March 2024 and based on my knowledge and belief, I state that:
  - a. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
  - b. these statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- 2. I further state that to the best of my knowledge and belief, no transactions entered into by the listed entity during the year which are fraudulent, illegal or violative of the listed entity's code of conduct.
- 3. I accept responsibility for establishing and maintaining internal controls for financial reporting and that they have evaluated the effectiveness of internal control systems of the listed entity pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- 4. I have indicated, based on my evaluation, wherever applicable, to the Auditors' and the Audit Committee:
  - a. significant changes in internal control over financial reporting during the year, if any;
  - b. significant changes, if any, in accounting policies during the year and that the same has been disclosed in the notes to the financial statements; and
  - c. instances of significant fraud of which they have become aware and the involvement therein, if any, of the management or an employee having a significant role in the listed entity's internal control system over financial reporting.

For and on behalf of Kabra Drugs Limited

Sd/-B.V. Ananth Kumar Chief Financial Officer

## CERTIFICATE OF COMPLIANCE WITH THE CODE OF CONDUCT FOR BOARD OF DIRECTORS

To, The Board of Directors KABRA DRUGS LIMITED Indore

All the members of the Board and Senior Management Personnel have affirmed compliance with the Code of Conduct in respect of the financial year ended March 31, 2024.

By the Order of the Board Kabra Drugs Limited

Sd/-KN.ANAND Director DIN: 03230186

Indore 02.09.2024

# CERTIFICATE ON COMPLIANCE WITH THE CONDITIONS OF CORPORATE GOVERNANCE UNDER THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

#### To the members of KABRA DRUGS LIMITED

We have examined the compliance of conditions of Corporate Governance by M/s. KABRA DRUGS LIMITED ("the company") for the year ended March 31, 2024, as per the provisions of regulations 17-27, clauses (b) to (i) of Regulation 46(2) and paragraphs C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to a review of the procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance as stipulated above. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us and based on the representations made by the Directors and the management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above-mentioned Listing Regulations, as applicable.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

#### Restrictions on Use

This certificate is issued solely for the purpose of complying with the aforesaid Regulations and may not be suitable for any other purpose.

For, RISHI SEKHRI AND ASSOCIATES Chartered Accountants FRN: 128216W

Sd/-

CA RISHI SEKHRI PARTNER M.NO. 126656

Place: Mumbai Date: 02.09.2024

#### INDEPENDENT AUDITORS' REPORT

#### TO THE MEMBERS OF KABRA DRUGS LIMITED

#### Report on the Audit of the Standalone Financial Statements

#### **Opinion**

We have audited the standalone financial statements of **KABRA DRUGS LIMITED** ("the Company"), which comprise the Standalone Balance Sheet as at 31 March 2024, and the Standalone Statement of Profit and Loss (including other comprehensive income), Standalone Statement of Changes in Equity and Standalone Statement of Cash Flows for the year then ended, and notes to the standalone financial statements, including a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2022, and profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

#### **Basis of Opinion**

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

#### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

There is no Key Audit Matters Reportable as per SA 701 issued by ICAI.

#### Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report but does not include the standalone financial statements and our auditors' report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

#### Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- (A) Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- (B) Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has an adequate internal financial controls system in place and the operating effectiveness of such controls.
- (C) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- (D) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- (E) Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial Statements for the financial year ended March 31, 2024, and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### Report on Other Legal and Regulatory Requirements

i. As required by the Companies (Auditor's Report) Order, 2016, issued by the Central Government of India in term of subsection (11) of section 143 of the Companies Act, 2013, we give in the Annexure "A" a statement on the matters specified in the paragraphs 3 and 4 of the Order, to the extent applicable.

As required by section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
- b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.
- c) The Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the Companies (Accounting Standards) Amendment Rules, 2016.
- e) On the basis of written representations received from the directors as on 31 March, 2024, taken on record by the Board of Directors, none of the directors is disqualified as on 31 March, 2024, from being appointed as a director in terms of Section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g) In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) which are required to be commented upon by us.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:
  - The Company does not have any pending litigation which would impact its financial position.
  - The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
  - There were no amounts which required to be transferred to the Investor Education and Protection Fund by the Company.

For, RISHI SEKHRI AND ASSOCIATES, Chartered Accountants FRN: 128216W

Sd/-CA RISHI SEKHRI PARTNER M.NO. 126656

UDIN: 23126656BGWLLN6208

Place: Mumbai Date: 30.05.2024

#### ANNEXURE "A" TO THE AUDITORS' REPORT

The Annexure referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of Our Report of even date to the members of M/s KABRA DRUGS LIMITED on the accounts of the company for the year ended 31st March 2024.

- 1. In respect of the Company's fixed assets:
  - a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has no immovable properties as at the end of the year.
- 2. The company does not have any inventory. Hence, clause (ii) (a) & (b) are not applicable to the Company.
- 3. As per information and explanation given to us, the company has not granted loans to parties covered in the register maintained under section 189 of the Companies Act hence clause (iii) (a) to (c) are not applicable to the company.
- 4. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans and investments made.
- 5. According to the information and explanations given to us, the Company has not accepted any deposits from the public. Therefore, the directives issued by the Reserve Bank of India and the provisions of sections 73 to 76 or any other relevant provisions of the Companies Act and the rules framed there under are not applicable to the Company.
- 6. As informed to us, Central government has not prescribed maintenance of cost records under sub-section (1) of section 148 of the Companies Act, in respect of products of the company.
- 7. In respect of Statutory dues:
  - 1. The Company is generally regular in depositing with appropriate authorities undisputed statutory dues including Provident Fund, Employees' State Insurance, Income Tax, Wealth Tax, Custom Duty, Goods and Service Tax, Cess and other material statutory dues applicable to it.
  - 2. According to the information and explanations given to us, no undisputed amounts payable in respect of outstanding statutory dues were in arrears as at March 31, 2022 for a period of more than six months from the date they became payable.
  - 3. According to the information and explanations given to us, following disputed amounts are payable as at March 31,

S.No.	Name of the statute	Nature of dues	As At 31/3/2019	Forum where dispute is
			(Rs. In lakhs)	pending
1	The Central Excise Act	Excise Duty	47.50	High Court MP

- 8. In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks. The Company has not taken any loan either from financial institutions or from the government and has not issued any debentures.
- 9. Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised money by way of initial public offer or further public offer including debt instruments and term Loans. Accordingly, the provisions of clause 3 (ix) of the Order are not applicable to the Company and hence not commented upon.
- 10. Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its Officers or employees has been noticed or reported during the year.
- 11. Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act.
- 12. In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 3 (xii) of the Order are not applicable to the Company.

### 35 | Page KABRA DRUGS LIMITED

- 13. In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.
- 14. Based upon the audit procedures performed and the information and explanations given by the management, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of clause 3 (xiv) of the Order are not applicable to the Company and hence not commented upon.
- 15. Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company and hence not commented upon.
- 16. In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order is not applicable to the Company and hence not commented upon.

For, RISHI SEKHRI AND ASSOCIATES, Chartered Accountants FRN: 128216W

Sd/-CA RISHI SEKHRI PARTNER M.NO. 126656

UDIN: 23126656BGWLLN6208

Place: Mumbai Date: 30.05.2024

#### Annexure "B" to the Auditors' Report

Report on the internal financial controls with reference to the aforesaid standalone financial statements under section 143(3)(i) of the Companies Act, 2013

We have audited the internal financial controls with reference to financial statements of **KABRA DRUGS LIMITED** ("the Company") as of March 31, 2024, in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

#### **Opinion**

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to standalone financial statements and such internal financial controls were operating effectively as at 31 March 2024, based on the internal financial controls with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance **Note").** 

#### Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as "the Act").

#### **Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to standalone financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to standalone financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the Auditors' judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

#### Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For, RISHI SEKHRI AND ASSOCIATES, Chartered Accountants

FRN: 128216W

Sd/-CA RISHI SEKHRI PARTNER M.NO. 126656

UDIN: 23126656BGWLLN6208

Place: Mumbai Date: 30.05.2024

Particulars	Note Ref	ST MARCH, 2024  As at March 31, 2024	As at March 31, 2023
ASSETS	Kei		
(1) Non-current Assets			
(a) Property, plant and equipment	1		
(b) Other Intangible Assets	1	-	-
(c) Financial Assets			
(i) Other Financial Assets			
(d) Defered Tax Assets (Net)		-	-
(e) Other non-current assets	2	2 21 669	2 21 660
(e) Other non-current assets	2	2,31,668	2,31,668
(2) Current Assets	<del> </del>	2,31,668	2,31,668
(a) Inventories			
(b) Financial Assets			
(i) Trade Receivables	3	60,04,761	60,04,761
(ii) Cash & Cash Equivalents	4	2,67,09,726	29,496
(iii) Bank Balance other than (ii) above	"	2,07,03,720	29,490
(iv) Loans	5	4,35,505	4,35,505
(c ) Other Current Assets	6	1,23,33,648	3,34,315
(c) other current Assets	"	4,54,83,641	68,04,078
TOTAL ASSETS		4,57,15,309	70,35,746
		4,57,23,363	70,00,140
EQUITY AND LIABILITIES			
EQUITY	7	4 20 00 000	4 30 00 000
(a) Equity Share Capital	7	4,38,86,000	4,38,86,000
(b) Other Equity	8	(5,85,57,378)	(5,11,96,437)
(c) Share Application Money		2,55,00,000	(72.40.427)
TOTAL EQUITY		1,08,28,623	(73,10,437)
LIABILITIES			
(1) Non - Current Liabilities			
(a) Financial Liablities			
(i) Borrowings		-	-
(2) Current Liabilities		-	<u>-</u>
(a) Financial Liabilities			
(i) Borrowings	9	1,70,84,503	1,38,18,999
(ii) Trade Payables		-	
(ii) Other financial liability	10	- 1 70 02 102	- 5
· ·	10	1,78,02,183	5,27,183
(b) Other Current Liabilities		2 V8 8E E0E	1 /12 /16 107
TOTAL EQUITY AND LIABILITIES		3,48,86,686 <b>4,57,15,309</b>	1,43,46,182 <b>70,35,746</b>

Statement of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss. As per our Report of even date

For RISHI SEKHRI AND ASSOCIATES

For and on Behalf of the Board

Chartered Accountants FRN: 128216 W

Sd/- Sd/- Sd/-

CA RISHI SEKHRIKN.ANANDB V ANANTH KUMARPartnerDirectorWTD & CFO

**UDIN: 23126656BGWLLN6208** DIN: 03230186 DIN: 08644948

 M. No.: 126656
 Place: Indore

 Place: Mumbai
 DATE: 30.05.2024

DATE: 30.05.2024

#### STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2024

Particulars	Note No	F.Y. 2023-24	F.Y. 2022-23
I. Revenue from Operations		-	-
II. Other Income	11	-	63,764
III. Total Revenue (I +II)		63,764	63,764
IV. Expenses:			
Cost of Material Consumed		-	-
Purchase of Stock-in-Trade		-	-
Change in inventories of finished goods & work in progress		-	-
Employee Benefit Expense	12	40,04,347	23,15,682
Financial costs		-	-
Depreciation & Amortisation	13	-	-
Other Expenses	14	33,56,594	11,27,085
IV. Total Expenses		73,60,941	34,42,767
V. Profit/(loss) before exceptional items and tax (III-IV)	(III - IV)	(73,60,941)	(33,79,003)
VI. Exceptional Items		-	-
VII. Profit/(loss) before tax (V-VI)	(V-VI)	-	-
VIII. Tax Expense:			
(1) Current Tax			
- Income Tax		-	-
(2) Earlier Year Tax			
- Short/(Excess) Provision of Tax		-	-
(3) Deferred Tax		-	-
(4) MAT Credit entitlement		-	-
IX.Profit/(Loss) for the period from Continuing Operations	(VII - VIII)	(73,60,941)	(33,79,003)
X. Other Comprehensive Income			
A (i) Items that will not be reclassified to profit or loss		-	-
(ii) Tax relating to items that will not be reclassified to profit or loss		-	-
Other Comprehensive Income for the year, net of tax		-	-
XI. Total Comprehensive Income for the period		(73,60,941)	(33,79,003)
X.Earning per equity share (Basic and Diluted)		(1.66)	(0.77)

Significant Accounting Policies & Notes on Accounts

15

The schedule referred above to form an integral part of the Profit & Loss in our report of even date.

For, RISHI SEKHRI AND ASSOCIATES

For and on Behalf of the Board

Chartered Accountants FRN: 128216 W Sd/-

CA RISHI SEKHRI Sd/- Sd/-

(Partner) KN.ANAND B V ANANTH KUMAR

 UDIN: 23126656BGWLLN6208
 Director
 WTD & CFO

 M. No.: 126656
 DIN: 03230186
 DIN: 08644948

Place: Mumbai Place: Indore
DATE: 30.05.2024 DATE: 30.05.2024

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2024

Dowleylare	31.03.2024	31.03.2023
Particulars	Rupees	Rupees
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before tax and extra ordinary items	(73,60,941)	(33,79,003)
Adjustment For :		
Depreciation/amortization on continuing operation	-	-
Interest expenses	-	-
Interest Income	-	-
Excess allowance for doubtful debts reversed	-	-
Loss on sale of Fixed assets	-	-
Operating profit before working capital changes	(73,60,941)	(33,79,003)
Movement in Working Capital :		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	-	-
Increase/(decrease) in Short Term Loan & Advances	-	2,77,680
Increase/(decrease) in Current Liabilities	-	-
Increase/(decrease) in Trade Payable	(1,72,75,000)	(4,42,979)
Increase/(decrease) in Other Current Assets	(1,19,99,333)	-
Direct taxes paid (net of refunds)	-	-
Net Cash Flow from Operating Activities(A)	(20,85,274)	(35,44,302)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Investments /withdrawl in Partnership Firm	-	-
Purchase / Sale of Fixed Assets	-	-
Interest Received	-	-
Change in Bank balances not considered as cash	-	-
Increase/(decrease) in Long Term Loan & Advances	-	-
Increase/(decrease) in other non-current Asset	-	-
Net Cash Flow from Invesing Activities(B)	-	-
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceed (Repayment) from long term borrowing	-	-
Proceed (Repayment) from short term borrowing	32,65,504	35,61,175
Proceed (Repayment) from Share Application Money	2,55,00,000	
Net Cash Flow from Financing Activities(C)	2,87,65,504	35,61,175
Net increase/(decrease) in cash & cash equivalents(A+B+C)	2,66,80,230	16,873
Cash and Cash equivalents (Opening Balance)	29,496	12,623
Cash and Cash equivalents (Closing Balance)	2,67,09,726	29,496

Previous year figure have been regrouped/ reclassified wherever necessary

As per our report of even date

For, RISHI SEKHRI AND ASSOCIATES

**Chartered Accountants** 

FRN: 128216 W

For and on Behalf of the Board

Sd/- Sd/-

CA RISHI SEKHRI KN.ANAND B V ANANTH KUMAR

 Partner
 Director
 WTD & CFO

 UDIN:23126656BGWLLN6208
 DIN: 02027009
 DIN: 08644948

M. No.: 126656 Place: Indore
Place: Mumbai DATE: 30.05.2024

DATE: 30.05.2024

#### Notes to Accounts for year ended March 31, 2024

#### **8(A)** Equity Share Capital

Equity share capital of face value `10.00 each	No. of Shares	(Figures in Rs.)
Balance as at April 1, 2022	4388600	43886000
Changes in equity share capital during the year	0	0
Balance as at March 31, 2023	4388600	43886000
Changes in equity share capital during the year	0	0
Balance as at March 31, 2024	4388600	43886000

8(B)

Other equity							
		Reserves and Surplus				Other Comprehensive Income	
	Capital Reserve	Special Reserve	General Reserve	Retained Earnings	Equity Instrument through OCI	Total	
Balance at the beginning of the reporting period on 1st April 2022	0	0	0	(4,78,17,434)	0	(4,78,17,434)	
Profit for the period	0	0	0	(33,79,003)	0	(33,79,003)	
Other Comprehensive Income for the year	0	0	0	0		0	
Balance as on 31st March 2023	0	0	0	(5,11,96,437)	0	(5,11,96,437)	
Profit for the period	0	0	0	(73,60,941)	0	(73,60,941)	
Other Comprehensive Income for the year	0	0	0	0	0	0	
Balance as on 31st March 2024	0	0	0	(5,85,57,378)	0	(5,85,57,378)	

Statements of significant accounting policies and other explanatory notes form part of the balance sheet and statement of profit and loss.

### As per our Report of even date

### For, RISHI SEKHRI AND ASSOCIATES

For and on Behalf of the Board

Chartered Accountants FRN: 128216 W

Sd/- Sd/- Sd/-

CA RISHI SEKHRI KN.ANAND B V ANANTH KUMAR

 Partner
 Director
 WTD & CFO

 M. No.: 126656
 DIN:03230186
 DIN: 08644948

Place: Mumbai Place: Indore DATE: 30.05.2024 DATE: 30.05.2024

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of equity shares is entitled to one vote per share.

The Company declares and pays dividend in Indian Rupees. The dividend proposed by the Board of directors is subject to the approval of the shareholders in ensuing Annual General Meeting. In event of liquidation of the Company, the holders of equity shares would be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The Distribution will be in proportion to the number of equity shares held by the shareholders.

#### Notes forming part of the financial statements

#### **General Information**

Kabra Drugs Limited is a limited company incorporated under The Companies Act, 1956 on 22<sup>nd</sup> August 1989 having its registered office at 270 Shastri Market Indore, MP. Company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products. The company is a public limited Company and its shares are listed on Bombay stock exchange (BSE).

#### **Basis of preparation**

The financial statements of the Company have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP). The company has prepared these financial statements to comply in all material respects with the accounting standards notified under Section 133 of the Companies Act, 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Amendment Rules, 2016. The financial statements have been prepared on an accrual basis and under the historical cost convention. The accounting policies adopted in the preparation of financial statements are consistent with those of previous year, except for the change in accounting policy explained below.

#### Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Differences between actual results and estimates are recognised in the period in which the results are known/materialized.

#### **Interest and Dividend**

Interest income is recognized on accrual basis using the effective interest method. No Dividend income is earned by the company.

#### **NON-CURRENT ASSETS**

#### **NOTE 1: PROPERTY, PLANT & EQUIPMENTS**

(In	١,
,	,

	T	(,,,
Particulars	Vehicle	Total
Gross Block		
As on 01/04/2022	16,62,621	16,62,621
Additions	-	-
Adjustments	-	-
As on 31/03/2023	16,62,621	16,62,621
Additions	-	-
Adjustments	-	-
As on 31/03/2024	16,62,621	16,62,621
Accumulated Depreciation		-
As on 01/04/2022	15,62,830	15,62,830
For the year 2022-23	99,791	99,791
Adjustments	-	-
As on 31/03/2023	16,62,621	16,62,621
For the year 2023-24	-	-
Adjustments	-	-
As on 31/03/2024	16,62,621	16,62,621
Net Block as on 31/03/2023	-	-
Net Block as on 31/03/2024	-	-
Previous Year	99,791	99,791

### **NON-CURRENT ASSETS**

#### **NOTE 2: OTHER NON-CURRENT ASSETS**

Particulars	As at March 31, 2024	As at March 31, 2023
TDS Receivable	2,31,668	2,31,668
Total	2,31,668	2,31,668

## **CURRENT ASSETS**

### NOTE 3 : FINANCIAL ASSETS- TRADE RECEIVABLES

Particulars	As at March 31, 2024	As at March 31, 2023
UNSECURED, CONSIDERED GOOD:		
(a) Outstanding for a period exceeding six months from the date they are due for payment	60,04,761	60,04,761
	60,04,761	60,04,761
UNSECURED, CONSIDERED DOUBTFUL:  (a) Outstanding for a period exceeding six months from the		
date they are due for payment	11,50,906	11,50,906
	11,50,906	11,50,906
Less: Provision for doubtful Debts	11,50,906	11,50,906
Total	60,04,761	60,04,761

#### NOTE 4: FINANCIAL ASSETS- CASH AND CASH EQUIVALENT

Particulars	As at March 31, 2024	As at March 31, 2023
Balances with Bank		
- Current account	2,55,45,100	14,870
- FD account	-	-
Cash in hand	11,64,626	14,626
Total	2,67,09,726	29,496

#### **NOTE 5: FINANCIAL ASSETS -LOANS CURRENT**

Particulars	As at March 31, 2024	As at March 31, 2023
Security Deposits	4,35,505	4,35,505
Total	4,35,505	4,35,505

### **NOTE 6 : OTHER CURRENT ASSETS**

Particulars	As at March 31, 2024	As at March 31, 2023
Balance with Government Authority	68,004	68,004
Advance to supplier	1,20,65,644	66,311
Advance Rent	2,00,000	2,00,000
Total	1,23,33,648	3,34,315

## NOTE 7 : EQUITY SHARE CAPITAL

Particulars	As at Marc	h 31, 2024	As at Ma	rch 31, 2023
A. Authorised: 50,00,000 eq. Shares of Rs.10 Each	-	5,00,00,000	-	5,00,00,000
Total	-	5,00,00,000	-	5,00,00,000
B. Issued, Subscribed & Fully Paid-up: 43,88,600 Eq. Shares of Rs.10 Each	-	4,38,86,000	-	4,38,86,000
Total	-	4,38,86,000	-	4 ,38,86,000

#### **Disclosures:**

## (i) Details of Shareholding in excess of 5%

Name of Shareholder	As at March 31, 2024		As at March 31, 2023	
	Number of Shares held	%	Number of Shares held	%
Shyam Kabra	-	0	-	0
Kusum Kabra	-	0	-	0
Ayush Kabra	-	0	-	0

# NOTE 8 : OTHER EQUITY (In `)

NOTE OF OTHER EQUIT		(1111 /
Particulars	As at March 31, 2024	As at March 31, 2023
(a) Capital reserve	-	-
(b) Security Premium	-	-
(C) Retained Earnings	(5,85,57,378)	(5,11,96,437)
(d) Geenral Reserve	-	-
Total	(5,85,57,378)	(5,11,96,437)

### **CURRENT LIABILITIES**

## NOTE 9: Financial Liablities - Borrowings - Non Current

Particulars	As at March 31, 2024	As at March 31, 2023
UnSecured		
Inter corporate deposits	65,24,800	65,24,800
Loan from Director	1,05,59,703	72,94,199
Total	1,70,84,503	1,38,18,999

## NOTE 10 : OTHER FINANCIAL LIABILITIES - CURRENT

Particulars	As at March 31, 2024	As at March 31, 2023
Advance from Customers	1,72,75,000	-
Other Liablities	5,27,183	5,27,183
Total	1,78,02,183	5,27,183

## NOTE 11: OTHER INCOME

Particulars	As at March 31, 2024	As at March 31, 2023
Profit /(Loss) from Partnership Firm	-	-
Interest Income	-	63,764
Dividend Received	-	-
Excess Allowance for doubtful trade receivable reversed	-	-
Profit on Sale of Land	-	-
Other Income	-	-
Total	-	63,764

Note: 12 Employment Benefit Expenses

Particulars	F.Y. 2023-24	F.Y. 2022-23
Salary, Wages and Other Benefits	40,04,347	23,15,682
Contribution to Provident and Other Funds	-	-
Staff Welfare expenses	-	-
Total	40,04,347	23,15,682

## Note: 13 Depreciation & Amortisation

Particulars	F.Y. 2023-24	F.Y. 2022-23
Depreciation on		
Tangible assests	-	-
Amortisation of Expenses		
Amalgamation Expenses		
<u>Total</u>	-	-

Note: 14 Other Expenses

Particulars	F.Y. 2023-24	F.Y. 2022-23
Advertisement Expense	1,85,575	87,110
Annual Custody Fees	14,018	12,721
Audit Fees	15,000	15,000
Bank Charges	5,468	3,101
Donation Expense	4,100	1,00,000
Electricity Expense	-	10,015
e-Voting Expense	-	5,900
Insurance Expense	-	7,000
Legal & Professional Expenses	1,85,575	4,43,000
Listing Fees -BSE	7,17,300	-

Miscellaneous Expenses	3,10,593 3,55,800	1,15,781
Rent Expense		2,34,000
ROC Filing Fees	13,50,000	10,500
RTA Fees	1,33,900	30,000
Telephone Expense	-	1,532
Travelling Expense	-	33,569
Website Expense	5,000	17,856
Total	33,56,594	11,27,085

#### Notes forming part of the financial statements

#### Basis of preparation

The financial statements of the Company have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP). The company has prepared these financial statements to comply in all material respects with the accounting standards notified under Section 133 of the Companies Act, 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Amendment Rules, 2016. The financial statements have been prepared on an accrual basis and under the historical cost convention. The accounting policies adopted in the preparation of financial statements are consistent with those of previous year, except for the change in accounting policy explained below.

#### Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Differences between actual results and estimates are recognised in the period in which the results are known / materialised.

Note: 15 Significant Accounting Policies:

#### a. General:

- Accounting policies not specifically referred to otherwise are in consistence with earlier year and in consonance with generally accepted accounting principles.
- ii) Expenses and income considered payable and receivable respectively are accounted for on accrual basis.
- **b.** Valuation of Inventories: There is no Inventories in the company.
- c. Fixed assets and depreciation:
  - i. Fixed Assets are stated at cost of acquisition less accumulated depreciation and is inclusive of freight taxes, and incidental expenses relating to such acquisition.
  - ii. Depreciation on property, plant and equipment is provided on Straight-line method (SLM) as per the useful life of the assets in the manner as specified in Schedule II to the Companies Act, 2013. The estimated useful life of assets and estimated residual value is taken as prescribed under Schedule II to the Companies Act, 2013..
- **d. Investments:** Investments are valued at cost. In determining cost FIFO method is used.
- e. Foreign currency Transactions: There is no foreign currency transaction.
- f. Retirement Benefits: Provident fund and employees state insurance scheme contribution is not applicable to the company.
- g. Taxes on Income:
  - **Current Tax:** Provision for Income-Tax is determined in accordance with the provisions of Income-tax Act 1961. **Deferred Tax Provision:** Deferred tax is recognized, on timing difference, being the difference between the taxable incomes and accounting income that originate in one period and are capable of reversal in one or more subsequent periods.

Note: 16 Balances of Sundry Debtors, Creditors, Loans and Advances are subject to confirmation and reconciliation.

**Note: 17** In the opinion of the Board of directors, the current assets, Loans & advances are approximately of the value stated if realized in the ordinary course of business. The provision of all known liabilities is adequate and not in excess of the amount reasonably necessary.

Note: 18 No Remuneration paid to the directors during the year.

# 47 | Page KABRA DRUGS LIMITED

Note: 19 Transactions during the year with Related Parties

Name of the party Kuniamuthur Nanjappan Anand Monika Nishant Gattani Nature of transactions Unsecured Loan Salary Year ended 31st March 2024 (Rs. In Lakhs)

61.03 1.13

FOR & ON BEHALF OF THE BOARD

Sd/-

Note: 20 there is no reportable segment as per the contention of the management.

Note: 21 Basic and Diluted Earnings per share (EPS) computed in accordance with Accounting Standard (AS) 20 "Earning per Share"

Particulars	31.03.2024 Rs.	31.03.2023 Rs.
Numerator Profit / (Loss) after Tax	(73,60,941)	(33,79,003)
<b>Denominator</b> Weighted average number of Nos. Equity shares	4388600	4388600
EPS (Basic & Diluted) Numerator/Denominator	(1.68)	(0.77)

Note: 22

Payment to Auditor's	2023-24 Rs.	2022-23 Rs.
For Audit	15000	15000
For Company Matters	00	00

Note: 23 previous year figures have been regrouped and recasted wherever necessary.

Signature to Notes '1' to '23'
As per our report on even date

FOR RISHI SEKHRI & ASSOCIATES CHARTERED ACCOUNTANTS

FIRM NO: 128216 W

Sd/- Sd/-

(CA RISHI SEKHRI)KN.ANANDB V ANANTH KUMARPARTNERDIRECTORWTD & CFOM.No. 126656DIN: 03230186DIN: 08644948

PLACE: Mumbai DATE: 30.05.2024

DATE: 30.05.2024

## KABRA DRUGS LIMITED

CIN: L02423MP1989PLC005438 Registered Office: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh - 452011, India.

<b>ANNUAL</b>	<b>GENERAL</b>	<b>MEETING</b>	on 30.09.20	024 at 10.0	0 A.M. at	t registered	office of	the company
---------------	----------------	----------------	-------------	-------------	-----------	--------------	-----------	-------------

oxy for the registered shareholder of the Company. I/Westing of the Company

over at the entrance.

PROXY FORM

#### Form No MGT-11

(Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the companies (Management and Administration) Rules, 2014)

CIN	L02423MP1989PLC005438
Name of Company	KABRA DRUGS LIMITED
Reg. Office Address	208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh – 452011.
Name of the Member	
Registered Address	
E Mail Id	
Folio No./Client ID	

I/We, being the member (s) of KABRA DRUGS LIMITED hereby appoint

Name	
Address	
E mail Id	Signature
OR FAILING	G HIM
Name	
Address	
E mail Id	Signature
OR FAILING	G HIM
Name	
Address	
E mail Id	Signature

As my/ our Proxy to attend and vote for me/us on my/ our behalf at the Annual General Meeting of the Company to be held on 30.09.2024 at 10.00 A.M. at registered office of the company and at any adjournment thereof and respect of such resolution mentioned below:

Resolution No.	Resolution	*Optional		
Ordinary Business		For	Against	
1	Adoption of financial statement for the year ended 31st March 2024, together with Auditors' Report and Directors' Report			
2	To appoint a director in place of Mr. BANGALORE VENKATAKRISHNAPPA ANANTHKUMAR (Din No. 08644948) who retires by rotation, and being eligible, offers himself for re-appointment.			
3	Appointment of M/S PPN And Company Chartered Accountants, (FRN:013623S) as Statutory Auditors and fixing their Remuneration for an initial term of 5 years.			
Special Bus	iness			
4	RESOLVED FURTHER THAT, to shift registered office of the Company from 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh - 452011, India. to Kabra Drugs Ltd, No: 3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033,			
5	Approve The Re-Appointment Of Mr. B V Anatha Kumar (Din:08644948) as the Whole-Time Director of the Company for a term of 2 years			
6	Regularization of Mr. N. Aravind (Din: 01895602) as Managing Director on The Board of the Company			
7	Change In Designation of Mr. Kuniamuthur Nanjappan Anand (Din: 03230186) as the Executive Director of the Company:			

Signed on this day of 2024.	Affix Revenue Stamp

Signature of shareholder ....../ Signature of Proxy .....

#### NOTE:

- 1. This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.
- 2. For the Resolution, Explanatory Statement and Notes, please refer to Notice of the Annual General Meeting forming part of the Annual report
- 3. \*It is Optional to put a 'X' in the appropriate column against the Resolutions indicated in the Box. If you leave the 'For' or 'Against' column blank against any or all Resolutions, your Proxy will be entitled to vote in the manner as he/she thinks appropriate.

## Route Map to the venue of the AGM



## **BOOK-POST**

To,			

If undelivered, please return to: KABRA DRUGS LIMITED

Registered Office: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore,

Madhya Pradesh - 452011, India.